Almitas Capital LLC Design Therapeutics, Inc. Transaction History
Almitas Capital LLC
- $177 Million
- Q1 2025
A detailed history of Almitas Capital LLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Almitas Capital LLC holds 1,452,896 shares of DSGN stock, worth $6.22 Million. This represents 3.17% of its overall portfolio holdings.
Number of Shares
1,452,896
Previous 1,323,667
9.76%
Holding current value
$6.22 Million
Previous $8.17 Million
31.33%
% of portfolio
3.17%
Previous 3.98%
Shares
4 transactions
Others Institutions Holding DSGN
# of Institutions
101Shares Held
33.4MCall Options Held
4KPut Options Held
3.1K-
Sr One Capital Management, LP6.53MShares$27.9 Million11.4% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$18.1 Million3.17% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$9.87 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$8.36 Million0.47% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.82MShares$7.78 Million0.02% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $239M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...